NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 79 resultados LastUpdate Última actualización 17/08/2019 [15:05:00] pdf PDF

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days

Página1 de 4 nextPage   por página


COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS TO DETECT CANCER STEM CELL REPROGRAMMING AND PROGRESSION

NºPublicación: US2019247413A1 15/08/2019

Solicitante:

UNIV CALIFORNIA [US]

WO_2017214463_A1

Resumen de: US2019247413A1

In alternative embodiment, provided are methods and compositions for treating, ameliorating or preventing diseases and conditions, such as cancer, including cancers associated with stem cells such as, without limitation, myelodysplastic syndrome (MDS) and a myeloproliferative neoplasm like chronic myeloid leukemia (CML) or acute myeloid leukemia (AML), and ablating or killing cancer stem cells. In alternative embodiment, provided are a new set of biomarkers to detect leukemia stem cell reprogramming and CML progression. In alternative embodiment, provided are therapeutic targets for treating myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML) by targeting edited let-7 transcripts.

traducir

CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR

NºPublicación: US2019248799A1 15/08/2019

Solicitante:

PHARMACYCLICS LLC [US]

US_2019248798_A1

Resumen de: US2019248799A1

Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

traducir

CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR

NºPublicación: US2019248798A1 15/08/2019

Solicitante:

PHARMACYCLICS LLC [US]

US_2019248799_A1

Resumen de: US2019248798A1

Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

traducir

PHARMACEUTICAL COMPOSITION FOR TREATMENT OR REMISSION OF CHRONIC MYELOGENOUS LEUKEMIA

NºPublicación: US2019247338A1 15/08/2019

Solicitante:

DELTA FLY PHARMA INC [JP]

JP_WO2018074409_A1

Resumen de: US2019247338A1

The present application provides a pharmaceutical composition for use in treatment or remission of patients with chronic myelogenous leukemia, wherein the composition comprises, as active ingredients, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof, and 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide or a pharmacologically acceptable salt thereof, both of which are used at low doses.

traducir

NANO-VESICLES DERIVED FROM GENUS MORGANELLA BACTERIA AND USE THEREOF

NºPublicación: US2019249197A1 15/08/2019

Solicitante:

MD HEALTHCARE INC [KR]

KR_20190086351_A

Resumen de: US2019249197A1

The present invention relates to vesicles derived from genus Morganella bacteria and a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples derived from patients with a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease as compared to normal persons, and the vesicles suppressed the secretion of inflammatory mediators by pathogenic vesicles and suppressed the occurrence of cancer, so that the vesicles derived from genus Morganella bacteria may be usefully used for the purpose of developing a method for diagnosing a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease, and a composition for preventing or treating the diseases or an inflammatory disease

traducir

RECOMBINANT CHIMERIC ANTIGEN RECEPTOR GENE AND USE THEREOF

NºPublicación: US2019249142A1 15/08/2019

Solicitante:

YIMING CELL BIOTECH LTD [CN]

Resumen de: US2019249142A1

The invention provides a recombinant chimeric antigen receptor (CAR) gene, a vector containing the same, a CAR-T cell and a use thereof. The recombinant CAR gene comprises a nucleic acid sequence encoding an antigen-binding portion of a CD30 antibody, a transmembrane portion and a CD137 cytoplasmic functional region and a CD3zeta cytoplasmic functional region linked in any order; also provides a method of treating Hodgkin's lymphoma or anaplastic large cell lymphoma or other CD30-positive tumors using the CAR-T cells of the invention.

traducir

AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA

NºPublicación: EP3523276A1 14/08/2019

Solicitante:

UNIV MARYLAND [US]
MCDANIEL COLLEGE [US]

CA_3039191_A1

Resumen de: WO2018067842A1

The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.

traducir

CS1 SPECIFIC MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR

NºPublicación: EP3524616A1 14/08/2019

Solicitante:

CELLECTIS [FR]

JP_2017518071_A

Resumen de: EP3524616A1

The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen CS1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen CS1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially multiple myeloma.

traducir

METHOD TO PREDICT THE NEED FOR THERAPY OF PATIENTS SUFFERING FROM CHRONIC LYMPHOCYTIC LEUKEMIA

NºPublicación: WO2019149736A1 08/08/2019

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV TOULOUSE 3 PAUL SABATIER [FR]
CENTRE NAT RECH SCIENT [FR]
CT HOSPITALIER UNIVERSITAIRE TOULOUSE [FR]
UNIV TOULOUSE 1 CAPITOLE [FR]

Resumen de: WO2019149736A1

The present invention relates to the prediction of the need for therapy of patients suffering from chronic lymphocytic leukemia (CLL). Here, the inventors developed a procedure to investigate whether CD8+T cell compartment is sculptured by disease progression and to evaluate the prognostic value of this compartment shaping, by applying a combination of statistical tools to flow cytometry data. Their results reveal that the CD8+T cell phenotype is imprinted by tumor progression in CLL patients. They identify a phenotypic signature combining at least 6 unrelated markers that describes the evolution towards therapy within 6 months after phenotyping in fresh whole blood samples, which was never done before and which allow the stratification of patients. The invention relates to a method for identifying phenotypical signatures within CD8+ lymphocytes to predict the need for therapy of a patient suffering from CLL comprising several steps.

traducir

5-ALKYLTHIO-7-(4-ARYLBENZYL)AMINO-1(2)H-PYRAZOLO4,3-DPYRIMIDINES FOR TREATMENT OF LYMPHOMA

NºPublicación: WO2019149295A1 08/08/2019

Solicitante:

UNIVERZITA PALACKEHO V OLOMOUCI [CZ]
USTAV EXPERIMENTALNI BOTANIKY AV CR V V I [CZ]

CZ_201858_A3

Resumen de: WO2019149295A1

The present invention relates to 5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidine derivatives of formula I which are effective inhibitors of kinases and exhibit strong antiproliferative and proapoptotic properties on lymphoma cells. This invention further relates to use of said derivatives in the treatment of blood hyperproliferative diseases, such as Non-Hodgkin lymphomas.

traducir

COMBINATION THERAPY USING ADOPTIVE CELL THERAPY AND CHECKPOINT INHIBITOR

NºPublicación: WO2019152743A1 08/08/2019

Solicitante:

CELGENE CORP [US]

Resumen de: WO2019152743A1

Provided are methods, compositions, uses and articles of manufacture of combination therapies involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and the use of a checkpoint inhibitor, such as an anti-PD-Ll antibody or antigen-binding fragment thereof for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a non-Hodgkin lymphoma (NHL), such as relapsed or refractory NHL or specific NHL subtype.

traducir

CD70 COMBINATION THERAPY

NºPublicación: US2019241668A1 08/08/2019

Solicitante:

ARGENX BVBA [BE]

WO_2019141732_A1

Resumen de: US2019241668A1

The present invention relates to combination therapies for the treatment of malignancy, particularly myeloid malignancy such as acute myeloid leukemia (AML). The combination therapies may include an antibody molecule that binds to CD70 and at least one antibody molecule that binds to a leukemic stem cell target. Preferred leukemic stem cell targets are TIM-3, IL1R3/IL1RAP and CD47.

traducir

FORMULATIONS AND METHODS FOR THE TREATMENT OF CANCERS

NºPublicación: US2019240198A1 08/08/2019

Solicitante:

TANG DEAN G [US]
CHEN XIN [CN]

Resumen de: US2019240198A1

The present invention is directed to a formulation for treating cancer comprising an androgen receptor signaling inhibitor and a B-cell-lymphoma-2 inhibitor, which may further comprising a Bromodomain-and-Extra-Terminal protein inhibitor or a phosphoinositide 3-kinase inhibitor.

traducir

COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME I

NºPublicación: US2019240241A1 08/08/2019

Solicitante:

BOEHRINGER INGELHEIM INT [DE]

US_2017157159_A1

Resumen de: US2019240241A1

The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Decitabine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

traducir

METHODS OF TREATMENT FOR MYELOID LEUKEMIA

NºPublicación: US2019240176A1 08/08/2019

Solicitante:

THE UNIV OF GEORGIA RESEARCH FOUNDATION INC [US]

WO_2018081372_PA

Resumen de: US2019240176A1

Embodiments of the present disclosure provide for methods of treating cancer (e.g., leukemia), pharmaceutical compositions for treating cancer, methods of modulating cancer progression and development, and the like.

traducir

PHARMACEUTICAL COMPOSITION COMPRISING AMORPHOUS LENALIDOMIDE AND AN ANTIOXIDANT

NºPublicación: US2019240157A1 08/08/2019

Solicitante:

SYNTHON BV [NL]

Resumen de: US2019240157A1

The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.

traducir

COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II

NºPublicación: US2019240242A1 08/08/2019

Solicitante:

BOEHRINGER INGELHEIM INT [DE]

US_2017157158_A1

Resumen de: US2019240242A1

The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Azacitidine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

traducir

COMBINATION OF ANTI CD19 ANTIBODY WITH A BCL-2 INHIBITOR AND USES THEREOF

NºPublicación: US2019241656A1 08/08/2019

Solicitante:

MORPHOSYS AG [DE]

KR_20190075942_A

Resumen de: US2019241656A1

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

traducir

INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS

NºPublicación: US2019241618A1 08/08/2019

Solicitante:

SIGNABLOK INC [US]

US_2013039948_A1

Resumen de: US2019241618A1

The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCRαβ-CD3δε-CD3γε-ζζ signaling complex. Yet more specifically, the peptides act on the TCRα/CD3δε/ζζ signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions. Specifically, the compositions are useful in the treatment and/or prevention of a disease or condition where T cells are involved or recruited. The compositions of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).

traducir

TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS

NºPublicación: US2019240222A1 08/08/2019

Solicitante:

CELGENE CORP [US]

US_2019240223_A1

Resumen de: US2019240222A1

Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).

traducir

TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS

NºPublicación: US2019240223A1 08/08/2019

Solicitante:

CELGENE CORP [US]

US_2019240222_A1

Resumen de: US2019240223A1

Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).

traducir

COMPANION DIAGNOSTIC FOR COMBINATION LENALIDOMIDE AND ERYTHROPOIETIN TREATMENT

NºPublicación: US2019240290A1 08/08/2019

Solicitante:

H LEE MOFFITT CANCER CENTER AND RES INSTITUTE INC [US]

WO_2018027144_A1

Resumen de: US2019240290A1

Disclosed herein is a companion diagnostic to predict efficacy of combination lenalidomide and erythropoietin treatment in patients with a erythropoietin (Epo)-refractory, Lower Risk (LR) Non-deletion 5q [Del(5q)] myelodysplasia syndrome (MDS). The method involves assaying erythroid precursors from a biological sample from the subject for a CD45 isoform profile, and treating the subject with a combination of lenalidomide and erythropoietin if the erythroid precursors have a predominance of large CD45RA and CD45RB isoforms compared to small CD45RO isoform.

traducir

A NOVEL INVADOPODIA-SPECIFIC MARKER OF INVASIVE CANCER STEM CELLS AND THE USE THEREOF

NºPublicación: US2019242900A1 08/08/2019

Solicitante:

TSAI KUN CHIH [TW]
YANG PATRICK YUHMIN [US]

WO_2018071154_PA

Resumen de: US2019242900A1

The present invention provides an invasive cancer stem cell (iCSC) or a substantively homogeneous cell population including said iCSC based on a cell-surface biomarker specifically localizing to the invadopodia of said iCSC. The present invention further provides an invasive leukemia stem cell (iLSC) or a substantively homogeneous cell population including said iLSC based on a cell-surface biomarker specifically localizing to the invadopodia of said iLSC. The present invention also provides a method or a kit of determining a diagnosis of aggressive solid tumor or hematopoietic cancer.

traducir

APPLICATION OF PLANT AS HOST IN EXPRESSION OF RITUXIMAB

NºPublicación: WO2019148938A1 08/08/2019

Solicitante:

WANG KEVIN [CN]

CN_110092833_A

Resumen de: WO2019148938A1

An application of a plant as a host in the expression of rituximab, a plant, such as lettuce, is used as an expression platform for recombinant protein production, and an Agrobacterium-mediated vacuum infiltration method is used to express a rituximab monoclonal antibody. The expression system determines that a foreign plant protein can be collected after four days of Agrobacterium infection. Successful expression of recombinant rituximab is determined by using a method of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Burkitt lymphoma inhibiting experiments demonstrate that rituximab produced by lettuce has the biological activity of inhibiting lymphoma cells.

traducir

5-CHLORO-2,4-PYRIMIDINE DERIVATIVE USED AS ANTI-TUMOR DRUG

Nº publicación: WO2019149128A1 08/08/2019

Solicitante:

LU KECHAO [CN]

Resumen de: WO2019149128A1

The present invention provides a 5-chloro-2,4-pyrimidine derivative used as an anaplastic lymphoma kinase (ALK) inhibitor. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt, prodrug, hydrate, solvent compound, metabolite of the compound represented by formula (I), wherein R1, R2, R3, R4, and R5 are as defined in the description. The compound and the pharmaceutical composition can be used as an ALK inhibitor and for preparing an anti-tumor therapeutic drug for inhibiting ALK.

traducir

Página1 de 4 nextPage por página

punteroimgVolver